Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler <i>versus</i> dual therapies in patients with COPD: a sub-study of the ETHOS trial.

In the KRONOS study, BGF 320/18/9.6 μg significantly improved FEV 1 AUC 0–4 at week 24 compared with BFF; however, the improvement in the change from baseline in morning pre-dose trough FEV 1 at week 24 for BGF 320/18/9.6 μg compared with GFF did not reach statistical significance. 9 Here, we report data from the ETHOS pulmonary function test (PFT) sub-study, which assessed the effect of BGF relative to GFF and BFF on lung function, including the effect on the rate of decline, in a subset of patients in the ETHOS study, throughout the 52-week treatment period.

also in 111,027 other papers